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Abstract
Background: Concomitant chemo-radiotherapy (CCRT) has become an indispensable organ, but not always
function preserving treatment modality for advanced head and neck cancer. To prevent/limit the functional side
effects of CCRT, special exercise programs are increasingly explored. This study presents cost-effectiveness analyses
of a preventive (swallowing) exercise program (PREP) compared to usual care (UC) from a health care perspective.
Methods: A Markov decision model of PREP versus UC was developed for CCRT in advanced head and neck
cancer. Main outcome variables were tube dependency at one-year and number of post-CCRT hospital admission
days. Primary outcome was costs per quality adjusted life years (cost/QALY), with an incremental cost-effectiveness
ratio (ICER) as outcome parameter. The Expected Value of Perfect Information (EVPI) was calculated to obtain the
value of further research.
Results: PREP resulted in less tube dependency (3% and 25%, respectively), and in fewer hospital admission days than
UC (3.2 and 4.5 days respectively). Total costs for UC amounted to €41,986 and for PREP to €42,271. Quality adjusted life
years for UC amounted to 0.68 and for PREP to 0.77. Based on costs per QALY, PREP has a higher probability of being
cost-effective as long as the willingness to pay threshold for 1 additional QALY is at least €3,200/QALY. At the prevailing
threshold of €20,000/QALY the probability for PREP being cost-effective compared to UC was 83%. The EVPI
demonstrated potential value in undertaking additional research to reduce the existing decision uncertainty.
Conclusions: Based on current evidence, PREP for CCRT in advanced head and neck cancer has the higher probability
of being cost-effective when compared to UC. Moreover, the majority of sensitivity analyses produced ICERs that are well
below the prevailing willingness to pay threshold for an additional QALY (range from dominance till €45,906/QALY).
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Background
In recent years, concomitant chemo-radiotherapy
(CCRT) has become an indispensable organ preserving
treatment modality for advanced head and neck cancer,
improving local control and overall survival in several
anatomical sites [1]. Unfortunately, CCRT can have a
detrimental effect on many functions of the upper
respiratory and digestive system. Sequellae such as pain,
oedema, xerostomia and fibrosis negatively affect mouth
opening (trismus), chewing, swallowing and speech [1].
Several studies investigating long-term effects of CCRT
have concluded that swallowing and nutritional dysfunc-
tion tend to be persistent and can be severe [2-4]. Not
surprisingly, therefore, CCRT can have a negative effect
on patients’ quality of life (QoL) [2]. Moreover, even
before onset of treatment patients may already present
with pain, impaired swallowing, trismus, aspiration,
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body weight, because the tumour may disrupt the normal
anatomy and thus interfere with normal function [1].
Many studies refer to the importance of rehabilitation
after, and even during treatment, in order to support and
improve those functions [2]. However, as yet, few studies
have investigated the effects of (preventive) rehabilitation
exercises on the predictable and inevitable swallowing
and mouth opening problems for this patient group. In
addition, little is known about the costs and benefits of
such exercise programs for head and neck cancer. As the
clinical effectiveness is established [4], it is now relevant
to embark on cost-effectiveness as a contribution to deci-
sion making on coverage.
The aim of this study was to analyze the incremental
cost-effectiveness for a preventive exercise program
(PREP) versus usual care (UC) for patients with advanced
head and neck cancer treated at the Netherlands Cancer
Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL).
Methods
Case description
To investigate the cost-effectiveness of a preventive
(swallowing) exercise program (PREP) compared to usual
care (UC) in advanced head and neck cancer, data of two
recent clinical trials in the Netherlands Cancer Institute
were used [3,4]. In both studies the protocol was
approved by the Protocol Review Board of the Nether-
lands Cancer Institute - Antoni van Leeuwenhoek Hospi-
tal (NKI-AVL) and written informed consent was
obtained from all patients before entering the study. All
patients had advanced (stage III and IV) functional or
anatomical inoperable head and neck cancer [5]. All
received identical concomitant chemo-radiotherapy
(CCRT), which consisted of 100-mg/m
2 Cisplatin as a 40
minutes intravenous (IV) infusion on days 1, 22, 43 and
combined with radiotherapy, and identical intensive sup-
portive care. Details about patients, methods, and clinical
results in both studies have been published previously
[3,4,6]. The patient characteristics are summarized in
Table 1.
The UC data are derived from a multi-center rando-
mized controlled trial (RCT), comparing intra-arterial (IA)
and intravenous (IV) chemo radiation in advanced head
and neck cancer [3]. Only the data of the 53 patients trea-
ted at the NKI-AVL, randomized in the IV arm, and still
alive and disease free at 12 months were analysed for this
cost-effectiveness study.
The PREP data are derived from a clinical trial con-
ducted immediately following the former RCT. In this
second RCT the effects of preventive strength and stretch
exercises on (long-term) swallowing and/or mouth open-
ing problems caused by CCRT, as an adjunct to UC,
were assessed in 55 advanced head and neck cancer
patients [4]. Before treatment all patients were rando-
mized into two groups: an experimental group that was
provided with the TheraBite
® Jaw Motion Rehabilitation
System™ and a group receiving standard intervention
(Standard group). The rationale and a detailed descrip-
tion of the exercises have been published previously [4].
In short, both regimes consist of comparable stretch and
strength exercises to keep the swallowing musculature
active before, during, and after CCRT, even when
patients are not swallowing because of (naso) gastric tube
feeding. Patients were encouraged to practice 3 times a
day and to integrate the exercises into other daily activ-
ities at home. Participants were provided with verbal and
written instructions prior to treatment, at which time
they also started practicing, thus, when oral intake was
not yet influenced by the treatment. Thirty-seven of the
55 included patients were still alive and disease free at
12-months. Since no significant differences in QoL, costs
and functional outcomes were found between the two
arms, for the present cost-effectiveness study both PREP
arms were taken together [4].
The main outcome variables of interest for this cost
effectiveness assessment were tube dependency at 12
months, and number of days patients were admitted to
the hospital after completion of the CCRT in the first year.
In the UC cohort, tube dependency was 13/53 (25%), and
in the PREP cohort 1/37 (3%). The mean number of extra
admission days in the hospital post-CCRT was 4.5 (SE 2.8)
in the UC, and 3.2 (SE 1.2) in the PREP cohort.
Model description
A Markov decision model was developed to compare the
PREP versus UC for advanced head and neck cancer. The
model was constructed with three mutually exclusive
health states: “complete remission”, “recurrent disease”
and “death” (death of cancer or other causes). The input
regarding treatment success rates, and probability of
recurrence were based on the published outcome data
from our institute [6]. We assumed that the PREP has no
direct influence on survival [7-9]. Input on aspiration for
UC was based on the empirical data, for PREP the value
was assumed, based on the literature. The input of feed-
ing substitutes and hospitalization were based on the
above-described databases: the series of Ackerstaff et al.
[3], as UC and that of Van der Molen et al. [4], as the
PREP strategy. The model simulated the course of events
in a hypothetical cohort of 1000 patients aged 55 years
with a stage III or IV squamous cell carcinoma of the
head and neck treated at the NKI-AVL. Possible compli-
cations from the treatment were modelled up to 1 year
from the start of treatment. The cycle length of the
model was one month, with a total simulated time
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health care perspective of the NKI-AVL. All costs were
reported in year 2008 Euros (Table 2).
Costs
In the NKI-AVL the costs for treatment where measured
by means of clinical pathways that patients followed when
receiving CCRT. Besides treatment costs, feeding substi-
tutes, pneumonia as adverse event and hospital days were
derived from the NKI-AVL hospital charts and administra-
tion. The professional costs of PREP were derived from the
Dutch Diagnosis Treatment Combination (DBC) “DBC-
system” list, this tariff includes all possible involved disci-
plines in the PREP (19-49 hours for €3,252). Use of feeding
substitutes (tube feeding) was calculated per disease sever-
ity stage from the two databases. It was assumed that from
the patients needing tube feeding, 50% received a nasal
tube and 50% received a gastronomy-tube (Table 2).
Health effects
The quality of life of patients treated with CCRT was
examined by Ackerstaff et al. [3]. For UC during treat-
ment the QoL result of 7 weeks was incorporated (0.517),
for UC after treatment, the QoL result of 12 months was
taken (0.754) [3]. Assumptions as to how these results
would be influenced by the PREP were based on pub-
lished literature and informal expert elicitation (Table 2).
Analysis
We programmed the model in Microsoft Excel (Micro-
soft, Redmond, WA) and validated it using various sensi-
tivity analyses. Future costs and effects were discounted
to their present value by a rate of 4% and 1.5% per year
respectively, according to Dutch guidelines [10]. Incre-
mental cost-effectiveness ratios (ICERS) were calculated
by dividing the incremental costs by incremental quality
adjusted life years (QALYs). Stochastic uncertainty in the
input parameters was handled probabilistically, by assign-
ing distributions to parameters (Table 2) [11]. Parameter
values were drawn randomly from the assigned distribu-
tions, using Monte Carlo simulation with 1000 iterations.
The results of the simulation of the hypothetical cohort
of 1000 patients are illustrated in a Cost-Effectiveness
(CE) plane, each quadrant indicates whether a strategy is
more or less expensive and more or less effective [12].
Cost-effectiveness acceptability curves (CEACs) to show
Table 1 Patient characteristics of the preceding randomized CCRT trial at in the NKI-AVL of Ackerstaff et al. (usual
care) [3] and the randomized CCRT trial at the NKI-AVL of Van der Molen et al. [4] that included a preventive
swallowing exercise program (PREP)
Usual care
N=5 3
PREP
N=3 7
Age in years
Median 55 58
Range 24-75 39-77
Sex
Male 36 (68%) 28 (76%)
Female 17 (32%) 9 (24%)
Stage distribution
III 14 (26%) 14 (38%)
IV 39 (74%) 23 (62%)
Tumour site
Oral cavity/oropharynx 16 (43%)
Hypopharynx 42 (79%) 15 (41%)
Nasopharynx 11 (21%) 6 (16%)
Follow up
Pre Pre
7 wks 10 wks
1-year 1-year
Tube dependency
before CCRT 8 (15%) 0 (0%)
1-year after CCRT 13/53 (25%) 1/37 (3%)
Aspiration at 1-year Unknown 1/37 (3%)
Hospital admission days after completion of CCRT (mean per patient/year) 4.49 3.19
Single day admissions after completion of CCRT (mean per patient/year) 0.70 0.16
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probability that a pathway has the highest net monetary
benefit, and thus is deemed cost-effective, for a range of
Willingness to Pay (l) values for one additional QALY,
also referred as the ceiling ratio. This definition involves
a Bayesian definition of probability i.e. the probability
that the hypothesis (’PREP is cost-effective compared to
UC’) is true given the data. The two curves therefore
always sum to 100% for one given value of l [13]. In the
Netherlands an informal ceiling ratio of €80,000 per
QALY exists (Dutch Council for Public Health and
Health Care 2006), and for preventive care programs of
€20,000 per QALY. The National Institute for Health and
Clinical Excellence in the United Kingdom uses a general
ceiling ratio between £20,000-£30,000 per QALY. In this
analysis, we use the Dutch threshold for preventive care
programs, €20,000 per QALY.
Sensitivity Analyses
We performed four one-way sensitivity analyses. The
first two sensitivity analyses tested the robustness of the
model outcomes against changes in the utility estimates
(i.e. higher and lower estimates), as the current esti-
mates are preliminary. For the two other sensitivity ana-
lyses, lower and higher cost estimates (€1,213 and
€7,058) were imported for the resource use associated
with paramedical care delivery in the rehabilitation pro-
gram (for respectively 7-18 hours or 50-129 hours). In
addition, we performed two two-way sensitivity analyses
to test the most uncertain parameters, such as a varia-
tion in utilities in combination with the various DBC
tariffs, and the variation of utilities in combination with
the probability of aspiration.
For various scenarios regarding costs and QALYs, we
also present the findings as cost-effectiveness acceptabil-
ity frontiers that illustrate the probability of any inter-
vention being optimal compared to its alternative. The
optimal intervention is defined as the one with the high-
est expected net health benefit. Each cost-effectiveness
frontier also illustrates the potential crossover when one
intervention is substituted by another as the one with
the highest probability of being optimal, and therefore
provides useful information for policy makers.
Expected value of perfect information (EVPI)
Uncertainty in the cost-effectiveness results was also pre-
sented and used to inform future research priorities
using Value of information analysis (VOI) analyses based
on the expected value of perfect information (EVPI). VOI
can be used to support decisions on focus and design of
further research, assuming that additional evidence on
the relevant aspects can be desired, but that the amount
and specific requirements for further research will
depend on the parameters which are causing the most
uncertainty [14]. Generally, information is valuable when
there is great uncertainty surrounding a decision and
when that decision likely affects a large number of people
in a meaningful way. If one had perfect information
Table 2 Input Parameters of base case and sensitivity
analysis, including days of feeding substitutes, treatment
success rates, aspiration probabilities, utilities and costs
Parameter Mean SE Distribution Source
Care
Days FS RB 2 months 0.760
a 4
Days FS UC 2 months 0.820 3
Days FS RB 3 months 0.370 4
Days FS UC 3 months 0.700 3
Days FS RB 12 months 0.030 4
Days FS UC 12 months 0.240 3
Success rates
CCRT 0.940
b 0.030 Beta 5
Recurrence rates 0.012
c 0.010 Beta 5
Aspiration PREP 0,027 0.015 Beta 4
Aspiration UC 0,054 0.015 Beta Assumption
Utilities
During CCRT PREP 0.617 0.015 Beta Assumption
During CCRT UC 0.517 0.015 Beta 3
Cured PREP 0.854 0.015 Beta Assumption
Cured UC 0.754 0.015 Beta 3
Recurrent disease 0.517 0.015 Beta Assumption
Costs
Hospital days NKI € 476 Fixed 8
Day care NKI € 229 Fixed 8
Feeding substitutes € 845 Fixed NKI-AVL
Professional Tariff € 3,252 Fixed DBC-system
CCRT € 31,000 Fixed NKI-AVL
Palliative care € 30,000 Fixed Assumption
Pneumonia € 1,904 Fixed 3, 4, 7
Sensitivity analysis
Utilities
During CCRT PREP low 0.567 0.015 Beta Assumption
During CCRT PREP high 0.667 0.015 Beta Assumption
Cured PREP low 0.804 0.015 Beta Assumption
Cured PREP high 0.904 0.015 Beta Assumption
Costs
Professional Tariff low € 1,214 Fixed DBC-system
Professional Tariff high € 7,058 Fixed DBC-system
PREP = preventive exercise program
UC = usual care
FS = feeding substitutes
NKI = Netherlands Cancer Institute
CCRT = concomitant chemo-radiotherapy
FS = Feeding substitutes
SE = Standard deviation
a calculated to monthly rate
b progression free survival probability of 50% over 5 years calculated to
monthly survival rate
c recurrence rate from ‘complete remission’ to recurrent disease
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decision makers in theory would always be able to make
correct choices regarding the use of the technology. The
difference between the expected net benefit obtained
using perfect information and the expected net benefit
obtained in the presence of uncertainty (that is, the maxi-
mum expected net benefit obtained with less than perfect
information) is known as the expected value of perfect
information (EVPI). It can be interpreted as the maxi-
mum amount the decision maker would be willing to
spend to obtain perfect information [15].
Results
Mean results
The total health care costs (treatment costs + preventive
exercises) per patient were: €42,271 for the preventive
exercise program (PREP), and €41,986 for usual care
(UC). The quality adjusted life years amounted to: 0.77
(PREP), and 0.68 (UC). The difference in costs per
QALY of the PREP strategy compared to the UC strat-
egy amounted to €285 (= 0.7% of the total treatment
costs). In comparison to UC, the PREP for advanced
head and neck tumours costs €3,197 per QALY gained
a n dw a sf o u n dt ob em o r ee f f e c t i v ea n ds l i g h t l ym o r e
costly (Table 3).
Uncertainty Analyses
When focusing on quality adjusted survival, the PREP has
a higher probability of being cost-effective compared to
UC, as long as the willingness to pay threshold for 1 addi-
tional QALY is at least €3,200/QALY (Figure 1 and 2). At
the prevailing threshold of €20,000/QALY the probability
for PREP being cost-effective compared to UC was 83%.
Sensitivity analyses
The sensitivity analysis using lower utility estimates
resulted in an incremental cost-effectiveness ratio (ICER)
of €6,393/QALY; higher utilities resulted in an ICER of
€2,131/QALY. The sensitivity analysis considering a
lower resource use (fewer hours of professionals) resulted
in UC being dominated by PREP, i.e. PREP is more effec-
tive and less costly than UC. Modelling a higher resource
use (more hours) for the PREP resulted in a higher ICER
of €45,906/QALY (Figure 3). The results of the two-way
sensitivity analyses are listed in Table 4, the majority of
the analyses resulted with an ICER below the ceiling ratio
of €20,000/QALY.
Expected value of information (EVPI)
At a ceiling ratio of €20,000/QALY the probability for
PREP being cost-effective compared to UC was 83%,
which shows a considerable decision uncertainty using
the current available data. The EVPI for the base case
resulted in €398,063, providing the upper boundary for
investing research funds in further clinical trials to
obtain perfect information on the cost-effectiveness of
PREP versus UC. The EVPI demonstrated potential
value in undertaking additional research to reduce the
existing decision uncertainty (Figure 4).
Discussion
This cost-effectives analysis, as based on two patient
populations with advanced head and neck cancer treated
with CCRT of which one was additionally treated with a
preventive exercise program (PREP) to prevent or limit
t h ef u n c t i o n a ls i d ee f f e c t so ft h et r e a t m e n t ,a n do n e
receiving no additional care, showed that quality-adjusted
survival was higher for the PREP. When focusing on
quality adjusted survival, PREP has an 83% probability of
being cost-effective at the prevailing threshold of
€20,000/QALY.
Because the presented results are based on preliminary
data, assumptions had to be made regarding the utilities
and no empirical data was yet available regarding
decrease of e.g. aspiration, which can be a life threaten-
ing problem in case of severe swallowing problems
resulting from CCRT. However, a quarter of the patients
in the usual care cohort needed a feeding tube at 12
months, in contrast to only 3% in the PREP cohort. This
s u g g e s t st h a tp a t i e n t si nt h eU Cg r o u pa r em o r el i k e l y
to suffer from aspiration than those in the PREP, some-
thing worthwhile to look into in more detail in future
studies. Furthermore, not all relevant improvements can
easily be expressed in costs or utilities and this may be
even more difficult because of the various different
effects that rehabilitation may have. E.g., it is likely that
the assumptions regarding the incremental utility of the
PREP and the probability of aspiration are an underesti-
mation, because patients’ functional improvement is
likely to become even better when patients are receiving
Table 3 Results of the base case analysis; incremental (difference) in QALYs, incremental costs and the incremental
cost-effectiveness ratio (ICER) of the comparison between Usual Care and PREP
Costs QALYs Incremental
COSTS
Incremental
QALYS
ICER
Costs/QALY
PREP €42,271 0.77 €285 0.09 €3,197*
Usual Care €41,986 0.68
*The numbers might not add up to 100% because of rounding; 284.8849/0.0891 = 3197.3614
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Page 5 of 9the full rehabilitation program. This is partly covered by
the sensitivity analyses but may also be investigated in
more detail with a Contingent Valuation study, where
someone’s willingness to pay for improvements in speci-
fic aspects of quality of life can be assessed.
Another limitation of this cost-effective analysis is that
the patient distribution in the two cohorts is not com-
pletely comparable. Although all patients had stage III
or IV disease, the distribution according to stage (more
stage IV in the UC group) and anatomical site (no oral
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Figure 1 Cost-Effectiveness plane; scatter plot showing the mean differences in costs and outcomes from the data using 1000
bootstrap replicates.
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Figure 2 Cost-effectiveness Acceptability Curves (CEAC); presenting the probability that the PREP is cost-effective compared with the
Usual Care for a range of values of thresholds (ceiling ratios, willingness to pay for one QALY).
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Page 6 of 9cavity/oropharynx in the UC group) was somewhat dif-
ferent. Next to this, the chemotherapy type and scheme
in both cohorts was identical except with respect to the
application of radiotherapy. In the IV arm of the study
of Ackerstaff et al. [3], roughly one fourth of the patient
population was treated with intensity-modulated radio-
therapy (IMRT), whereas in all patients in the study of
Van der Molen et al. [4] IMRT was applied. These dif-
ferences could have influenced the functional outcomes
in the two cohorts. Exact data about these aspects
unfortunately are not retrievable. But we are sufficiently
confident, that in the study of Ackerstaff et al. [3] most
of the patients that were disease free at 1-year, indeed
received IMRT.
Literature suggests that other functions will also
improve as a result of a PREP, and thus the cost-effective-
ness would most likely improve even more when these
other functions are taken into account [16-22]. Model
inputs for UC were based on a former study performed in
the Netherlands Cancer Institute (NKI-AVL) [3], to be
able to make a clear comparison. However, the NKI-AVL,
as a specialized tertiary care hospital, is a pioneer in this
field and thereby already had implemented some rehabili-
tation components in the UC-series of Ackerstaff et al. [3],
e.g. not ‘automatically’ providing a feeding tube at the
onset of treatment, but trying with intensified support to
maintain oral feeding for as long as possible. If the com-
parison was made with the care as provided by the
national guidelines at that time, the analysis would prob-
ably result in an even more favourable ICER.
Because of the promising results of this PREP, a more
comprehensive head and neck rehabilitation program
has been developed to stimulate participation in every-
day life activities with all the pathophysiological or ana-
tomical changes and restrictions accompanying head
and neck cancer taken into account. To achieve this, the
NKI-AVL is cooperating with the rehabilitation centre
Amsterdam (READE) to accomplish this comprehensive
rehabilitation program based on the ‘International Clas-
sification of Functioning, Disability and Health’ (ICF)
core sets for head and neck cancer [23]. It is conceivable
that such a more intensified program can boost rehabili-
tation results even further and research as to that is
planned.
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Figure 3 CEAC-frontiers; plotting the extent of uncertainty associated with the optimal strategy.
Table 4 Results of the two-way sensitivity analysis; range
of variables of utilities versus different DBC tariffs and
range of variables of utilities versus different aspiration
probabilities
Utilities 0.80 0.85 0.90
DBC tariffs
€1,214 -€ 39,349 -€ 19,674 -€ 13,116
€3,252 € 6,394 €3,197 € 2,131
€7,058 € 91,814 € 45,907 € 30,605
Utilities 0.80 0.85 0.90
aspiration
0.02 € 23,442 € 11,721 € 7,814
0.04 € 13,430 € 6,715 € 4,477
0.06 € 3,417 € 1,709 € 1,139
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decision model because this allows synthesizing data
from various sources, when an empirical, longer term,
head to head trial of PREP versus UC has not yet been
performed. As with all modelling studies that extrapo-
late data beyond the time horizon of a clinical trial, the
outcomes have to be interpreted as expected costs and
outcomes, based on the best available current evidence.
Conclusion
This study shows that, based on current available evidence,
the addition of a preventive (swallowing) exercise program
to concomitant chemo-radiotherapy in advanced head and
neck cancer improves quality-adjusted survival and has a
higher probability of being cost-effective compared to
usual care. The calculated additional costs of €3,200/
QALY is well below the threshold of €20,000/QALY,
which currently is handled for preventive care programs e.
g. by the Dutch Council for Public Health and Health
Care and the National Institute for Health and Clinical
Excellence in the United Kingdom. With a relatively low
additional investment in research the uncertainty in the
calculation of the cost effectiveness can be considerably
improved, which is currently ongoing.
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